110 related articles for article (PubMed ID: 1463110)
1. Phorbol dibutyrate plus ionomycin improves the generation of cytotoxic T cells from draining lymph nodes of patients with advanced head and neck cancer.
McGrath PC; Hamby LS; Freeman JW
Am J Surg; 1992 Dec; 164(6):610-4. PubMed ID: 1463110
[TBL] [Abstract][Full Text] [Related]
2. Activation of CD8+ murine T cells from tumor-draining lymph nodes by phorbol dibutyrate plus calcium ionophore.
Tuttle TM; Inge TH; McCrady CM; Bethke KP; Bear HD
J Immunother (1991); 1992 Jul; 12(1):32-40. PubMed ID: 1386251
[TBL] [Abstract][Full Text] [Related]
3. Phorbol dibutyrate and ionomycin improve murine effector cell cytotoxicity.
Hamby LS; Freeman JW; McGrath PC
J Surg Res; 1993 Feb; 54(2):115-21. PubMed ID: 8479168
[TBL] [Abstract][Full Text] [Related]
4. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma.
Sadeghi N; Black MJ; Hier MP; Shenouda G; Karp SE
Arch Otolaryngol Head Neck Surg; 1997 Jan; 123(1):25-30. PubMed ID: 9006500
[TBL] [Abstract][Full Text] [Related]
5. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
6. Modulation of in vitro autologous melanoma-specific cytotoxic T-cell responses by phorbol dibutyrate and ionomycin.
Darrow TL; Quinn-Allen MA; Crowley NJ; Seigler HF
Cell Immunol; 1990 Feb; 125(2):508-17. PubMed ID: 2297796
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice.
Chikamatsu K; Reichert TE; Kashii Y; Saito T; Kawashiri S; Yamamoto E; Whiteside TL
Int J Cancer; 1999 Aug; 82(4):532-7. PubMed ID: 10404067
[TBL] [Abstract][Full Text] [Related]
8. Activation of human T lymphocytes by phorbol-12,13-dibutyrate and ionomycin.
Larsen CS
Scand J Immunol; 1990 Mar; 31(3):353-60. PubMed ID: 2320954
[TBL] [Abstract][Full Text] [Related]
9. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
[TBL] [Abstract][Full Text] [Related]
10. Alteration of human lymphokine-activated killer cell activity by manipulation of protein kinase C and cytosolic Ca2+.
McCrady CW; Li F; Grant AJ; Merchant RE; Carchman RA
Cancer Res; 1988 Feb; 48(3):635-40. PubMed ID: 3257170
[TBL] [Abstract][Full Text] [Related]
11. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
[TBL] [Abstract][Full Text] [Related]
12. Differences of sensitivity to autologous cytotoxic lymphocytes between primary tumor and its cervical lymph node metastases.
Maehara T; Eura M; Ikawa T; Ishikawa T
Auris Nasus Larynx; 1987; 14(3):187-98. PubMed ID: 3502523
[TBL] [Abstract][Full Text] [Related]
13. Functional and phenotypic analysis of lymphocytes in head and neck cancer.
Snyderman CH; Heo DS; Johnson JT; D'Amico F; Barnes L; Whiteside TL
Arch Otolaryngol Head Neck Surg; 1991 Aug; 117(8):899-905. PubMed ID: 1832546
[TBL] [Abstract][Full Text] [Related]
14. [Study of head and neck cancer treatment by administration of autologous cytotoxic lymphocyte induced by stimulation with tumor cell--induction of killer cells by stimulation with allogeneic tumor cell].
Ikawa T; Ishikawa T; Eura M
Nihon Jibiinkoka Gakkai Kaiho; 1988 Dec; 91(12):2079-81. PubMed ID: 3266242
[No Abstract] [Full Text] [Related]
15. [Comparative study of the functional expression of the Na/K-pump in human lymphocytes, activated by phytohemagglutinin, phorbol ester, ionomycin, and interleukin-2].
Toropova FV; Vinogradova TA; Marakhova II
Tsitologiia; 2001; 43(2):148-55. PubMed ID: 11347470
[TBL] [Abstract][Full Text] [Related]
16. Bryostatin 1 activates T cells that have antitumor activity.
Tuttle TM; Inge TH; Wirt CP; Frank JL; McCrady CM; Bear HD
J Immunother (1991); 1992 Aug; 12(2):75-81. PubMed ID: 1504056
[TBL] [Abstract][Full Text] [Related]
17. Induction of tumoricidal activity and alterations of growth by interleukin-2 and manipulation of protein kinase C and cytosolic calcium in childhood acute lymphocytic leukemia cells.
Massey GV; McCrady CW; Dunn NL; Russell EC; Carchman RA
Leukemia; 1989 Aug; 3(8):602-10. PubMed ID: 2787455
[TBL] [Abstract][Full Text] [Related]
18. Activation and in vitro expansion of tumor-reactive T lymphocytes from lymph nodes draining human primary breast cancers.
Hoover SK; Frank JL; McCrady C; McKinnon JG; Bear HD
J Surg Oncol; 1991 Feb; 46(2):117-24. PubMed ID: 1825123
[TBL] [Abstract][Full Text] [Related]
19. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
20. Coordination and reversibility of signals for proliferative activation and interleukin-2 mRNA production in resting human T lymphocytes by phorbol ester and calcium ionophore.
McCrady CW; Ely CM; Westin E; Carchman RA
J Biol Chem; 1988 Dec; 263(34):18537-44. PubMed ID: 3263969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
